Vilon for Health & Longevity

Evidence Review created on 09/21/2026 using AI4L / Opus 5

Also known as: Lys-Glu, KE, L-Lysyl-L-Glutamic Acid, Lysylglutamate

Motivation

Vilon (Lys-Glu) is a synthetic molecule built from just two amino acids, lysine and glutamic acid. It was designed in Russia as a compact, defined replacement for thymus extracts, and interest in it rests on a single striking claim: that a molecule this small can enter the nucleus of a cell and switch particular genes back on.

Shrinkage of the thymus is one of the most consistent features of human ageing, and it tracks with weaker responses to infection and vaccination and with rising cancer risk. Vilon belongs to a family of short peptides studied in Russia for roughly three decades. It is a registered medicine in Russian pharmacies and, elsewhere, reaches people only through research-chemical suppliers. Almost everything published about it comes from the institute that created it.

This review examines what the published record on Vilon establishes and what it does not: the laboratory and animal findings, the small human studies, the results that point the other way, the dosing practice reported by the group that developed it, and the quality and access questions that follow from its unapproved status.

Benefits - Risks - Protocol - Conclusion

Grokipedia

Vilon

A dedicated article giving the chemical identity, molecular weight, development history and the gene-regulation and longevity claims in one place, with the Khavinson programme’s chronology set out more clearly than the primary papers manage.

Examine

No Examine article exists for Vilon. Examine.com indexes dietary supplements and does not cover compounds that are available only as a foreign-registered prescription medicine or as research-use-only material, which is Vilon’s entire distribution.

ConsumerLab

No ConsumerLab article exists for Vilon. ConsumerLab tests retail supplement products and does not cover compounds that are available only as a foreign-registered prescription medicine or as research-use-only material, so no product review or purity testing exists.

Systematic Reviews

Review-level literature touching Vilon, which at present covers the short-peptide class rather than the compound itself.

Peptide Regulation of Gene Expression: A Systematic Review - Khavinson et al., 2021

Synthesises the peptide–DNA binding evidence underpinning Vilon’s proposed mechanism; written by the peptide’s developers and covering the class rather than Vilon alone.

Only the claimed-effect side of the trade-off is represented at review level, and even there only at class level. No systematic review or meta-analysis addresses Vilon’s principal risk — the tumour-promotion signal seen in transgenic mice — or its clinical benefit claims, so the risk side of the trade-off is unrepresented.

Mechanism of Action

Vilon is L-lysyl-L-glutamic acid, a two-residue peptide weighing 275.3 daltons and carrying one positive and one negative charge.

Its developers propose direct gene regulation. Peptides this small cross cell and nuclear membranes unaided and bind double-stranded DNA; molecular modelling places lysyl-glutamic acid at GCGG and GGGC sequences found in the promoters of SIRT1 (a protein-deacetylating enzyme linked to stress resistance) and of PARP1 and PARP2 (enzymes that repair DNA breaks). In human mesenchymal stem cells (the connective-tissue precursor cells), the peptide raised SIRT1 in young cells and lowered both PARP genes during ageing.

The downstream effect is described as thymus-selective. Vilon stimulates growth of thymus tissue explants (tissue pieces kept alive in culture), drives division of thymocytes (immature T cells), and pushes cultured thymic precursors toward helper T cells. It also blunts apoptosis (programmed cell death) in irradiated lymphocytes.

A competing reading is that a charged dipeptide at these concentrations acts non-specifically — as an electrostatic ligand, or as free lysine and glutamate after hydrolysis — rather than by recognising sequences. No laboratory outside the originating group has reproduced the promoter-binding claim.

Pharmacology is thinly described. No human half-life, plasma concentration or tissue-distribution measurement exists. Free dipeptides are hydrolysed within minutes by serum and intestinal aminopeptidases and dipeptidases, not by cytochrome P450 enzymes (the liver’s main drug-metabolising family); oral absorption depends on the intestinal peptide transporter PEPT1. No receptor selectivity has been demonstrated.

Historical Context & Evolution

Vilon’s ancestry is military medicine, not longevity. In the 1970s Vladimir Khavinson, working at the S.M. Kirov Military Medical Academy, extracted peptide fractions from calf organs — thymus, pineal gland, cortex — to treat radiation injury and restore immune function in exposed personnel. The thymus extract, Thymalin, became the template. Through the 1980s and 1990s the programme moved from crude extracts to defined synthetic molecules of two to four residues, on the argument that one well-characterised peptide could reproduce an extract’s effect without its batch variability. Vilon, introduced in the late 1990s, was the thymic member of that second generation.

The turn toward health optimisation came from the animal work. Mice given Vilon from mid-life lived longer, stayed more active and developed fewer spontaneous tumours, and carcinogen-treated rats developed fewer bladder tumours. Cells taken from people in their late seventies and eighties showed loosening of tightly packed genetic material, which the group read as gene reactivation.

The record did not settle into agreement. A Russian–Italian collaboration found the opposite signal in mice engineered to overexpress HER2, a growth-signal receptor amplified in some human breast cancers: Vilon accelerated mammary tumours while a sister peptide suppressed them. Western reception has been cautious less because the findings were refuted than because almost none has been reproduced outside the originating institute, and the proposed mechanism has no independent confirmation. Both readings remain open.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: no clinical endpoint has been shown in more than one independent human trial, the human record being three small single-centre reports from two groups — one controlled trial in bowel cancer and two overlapping type 1 diabetes reports from the same investigators — with everything else rodent work, organ-culture explants and unvalidated cell-level markers.

Medium 🟩 🟩

Fewer Complications and Longer Survival When Added to Colorectal Cancer Treatment in Older Adults

Added to surgery, radiotherapy and chemotherapy for stage III rectal and colon cancer in older patients, Vilon was reported to reduce post-operative and late complications, recurrence and spread, and to raise two-year survival and quality of life. The evidence is a single small controlled clinical trial, described by its own authors as preliminary, with no randomisation or masking stated and no numerical results in the published record. No independent group has repeated it.

Magnitude: Direction favours Vilon on two-year survival, complication rate and recurrence when it is added to radical treatment of stage III disease in older patients; the report supplies no outcome figure, no confidence interval (the statistical range around an estimate) and no group sizes.

Low 🟩

Lower Insulin Requirement and Shifted Coagulation Markers in Older Adults With Type 1 Diabetes

In an add-on study, Vilon raised the natural anticoagulants antithrombin III and protein C, increased clot breakdown, and allowed insulin doses to be lowered in most patients; a companion randomised report from the same investigators found the same coagulation shift. Single centre, one group, no independent replication.

Magnitude: Direction is a fall in required insulin dose in most treated patients, with higher antithrombin III and protein C, in older adults already established on insulin; the report gives no dose change in units, no percentages and no measure of spread.

Speculative 🟨

Lower Scarring Signals and Vessel Leak in Rodent Kidney Failure

Two months after induced kidney failure, rats given Vilon had less of the scarring signal transforming growth factor beta-1 and reduced small-vessel leakage. Single rodent study, no human counterpart.

Protection of Lymphocytes From Radiation-Induced Cell Death

In irradiated rats, Vilon blunted apoptosis of spleen lymphocytes more strongly than a related peptide. A mechanistic rodent finding that equally raises the prospect of damaged cells surviving.

Improved Small-Intestine Enzyme Activity in Old Rats

One month of oral Vilon raised membrane and internal digestive enzyme activity in the small intestine of aged rats, which the authors read as better nutrient handling and barrier function. Rodent tissue measurement only.

Activated Sexual Function and Lower Prolactin in Old Male Rats

Vilon activated sexual function in old male rats with reduced testicular output and lowered prolactin (a hormone whose age-related rise blunts sexual function). One rodent study only.

Greater Resistance to Emotional Stress in Rats

Vilon improved open-field behaviour under emotional stress, prevented adrenal enlargement and thymus shrinkage, and reduced activation of the brain’s stress-command nucleus. One rodent study, no human measurement.

Suppressed Inflammatory Signalling in Human Monocyte Cultures

Alongside four related peptides, Vilon lowered the inflammatory signals tumour necrosis factor and interleukin-6 in bacterial-toxin-stimulated human monocytes and reduced their sticking to vessel-lining cells. A human cell line only.

Weak Liver Regeneration in Cirrhotic Rats

In rats with chemically induced liver scarring, five days of Vilon restored a sugar-releasing liver enzyme and slightly raised liver-cell protein. The authors called the regenerative effect weak; one rodent study.

Benefit-Modifying Factors

Genetic variation: No pharmacogenetic data exist for Vilon. The one variant with a plausible bearing is amplification of HER2 in breast tissue, the setting in which the peptide worsened outcomes in mice. Intestinal peptide-transporter variants could alter absorption of oral forms.
Baseline biomarker levels: Effects appeared in cells from people aged 75 to 88 and in old rodents, not in young tissue. A low naive T-cell fraction and low helper-to-cytotoxic T-cell ratio are the states where a thymic effect has room to show.
Sex-based differences: Every rodent lifespan and tumour experiment used female animals, and no human report gave results by sex. Whether men respond at all is untested rather than negative, and the breast-tissue tumour signal is specific to female tissue.
Pre-existing health conditions: The only reported human benefits arose in two disease settings, stage III colorectal cancer and type 1 diabetes. In people without an active immune or metabolic deficit, no benefit of any kind has been measured.
Age-related considerations: Loosening of packed genetic material became more pronounced with advancing age and was absent in certain regions regardless of age, so the oldest end of the target range is where an effect is most plausible and least studied.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: no adverse outcome has been documented in more than one human trial, none of the three published human reports sets out safety endpoints, and no post-marketing adverse-event dataset exists outside Russia.

Medium 🟥 🟥

No risk reaches Medium either: not one adverse outcome has been measured in even a single controlled human trial, the human-level signals below being secondary findings from an uncontrolled study.

Low 🟥

Reduction in Helper T Cells and Natural Killer Cells

The one human study to report immune counts found fewer helper T cells (which coordinate immune responses) and fewer natural killer cells (which destroy infected and tumour cells) during Vilon treatment — the opposite of the intended effect. Uncontrolled, single centre, unreplicated.

Magnitude: Direction is downward for helper T-cell and natural killer cell counts in older adults with type 1 diabetes receiving Vilon alongside standard therapy; the report gives no cell counts, no percentages and no measure of spread.

Hypoglycaemia When Combined With Insulin or Other Glucose-Lowering Treatment

The same study reported that insulin doses could be reduced in most patients, which implies added glucose lowering; where the insulin dose is not reduced, hypoglycaemia (abnormally low blood sugar) becomes possible. No hypoglycaemic events were reported or systematically collected.

Magnitude: Not quantified in available studies. No trial measured glucose excursions or counted hypoglycaemic episodes on Vilon, so the exposure can only be inferred from the reported reduction in insulin requirement.

Speculative 🟨

Tumour Promotion in Predisposed Tissue ⚠️ Conflicted

In HER2-driven transgenic mice Vilon raised breast-cancer incidence, brought tumours on sooner and increased tumour count, while other rodent models showed inhibition. Net reading: an unresolved, model-dependent hazard.

Antagonism of Cytotoxic Chemotherapy

Given at the same time as cyclophosphamide, Vilon shortened survival in tumour-bearing mice and cancelled the drug’s growth-inhibiting effect in spleen explants. The authors concluded the two should not be given simultaneously.

Unwanted Lymphoid Proliferation and Suppressed Cell Turnover

Vilon drives thymocyte division and inhibits programmed cell death in lymphocytes. The same actions credited with immune restoration could favour lymphoid overgrowth or survival of damaged cells. Basis is rodent and cell-culture work only.

De-Repression of Normally Silenced Genome Regions

Loosening packed genetic material in old cells, the claimed mechanism, would also lift silencing of repeat elements tied to inflammation and genome instability. No study has tested this.

Contamination, Mislabelling and Injection-Site Reactions From Research-Grade Supply

Outside Russia, Vilon reaches users as research-chemical powder with no verified identity, sterility or endotoxin testing (endotoxin is bacterial debris that causes fever). Local injection reactions and feverish responses are reported anecdotally only.

Risk-Modifying Factors

Genetic variation: No risk-modifying variant is established. HER2 amplification is the one biologically anchored concern, given the mouse mammary-tumour result, and carriers of inherited cancer-predisposition variants share the same theoretical exposure.
Baseline biomarker levels: Baseline helper T-cell and natural killer cell counts matter, because the single human immune dataset showed both falling and already-low counts leave less margin. Baseline glucose and insulin dose set the hypoglycaemia exposure.
Sex-based differences: The mammary-tumour signal came from female mice, so the breast-tissue concern weighs toward women. No male-specific risk has been examined, and no sex-stratified human safety data exist.
Pre-existing health conditions: Active or recent cancer, ongoing cytotoxic chemotherapy, autoimmune disease, transplant immunosuppression and therapeutic anticoagulation each intersect with a documented or mechanistically expected Vilon effect.
Age-related considerations: Older adults carry higher background cancer incidence and more concurrent medication, so the tumour-promotion and anticoagulant-interaction concerns weigh most heavily at the upper end of the target range.

Key Interactions & Contraindications

Alkylating cytotoxic chemotherapy — cell-killing cancer drugs (cyclophosphamide, ifosfamide, chlorambucil): Caution bordering on avoidance. Simultaneous dosing shortened survival in tumour-bearing mice and abolished the drug’s tumour-slowing effect. Mitigation: never overlap courses; separate by the drug’s washout interval.
Insulin and insulin-releasing tablets (glimepiride, gliclazide, repaglinide): Monitor. Additive glucose lowering, with hypoglycaemia as the consequence. Mitigation: increase glucose self-monitoring during each 10–20 day course and reduce insulin pre-emptively in small increments rather than after an event.
Anticoagulants and antiplatelet drugs — blood thinners (warfarin, apixaban, clopidogrel): Monitor. Vilon raised antithrombin III and protein C and increased clot breakdown, so bleeding risk may add. Mitigation: check the international normalised ratio (a standardised clotting time) within one week of starting.
Immunosuppressants — drugs that damp the immune system (ciclosporin, tacrolimus, prednisone at 20 mg daily or more): Caution; direct pharmacological opposition. An immune-activating peptide works against the therapeutic goal and could contribute to graft rejection or disease flare. Mitigation: avoid entirely.
Immune checkpoint inhibitors — drugs that release the immune brakes on tumours (pembrolizumab, nivolumab): Caution. Theoretical additive T-cell activation raising the risk of immune-related adverse events, with no data either way. Mitigation: avoid concurrent use outside direct oncology supervision.
Over-the-counter analgesics (aspirin, ibuprofen, naproxen): Monitor. Aspirin and other non-steroidal anti-inflammatory drugs (common pain relievers) add an antiplatelet effect to Vilon’s reported shift toward clot breakdown. Mitigation: avoid routine high-dose use and watch for bruising.
Other peptide bioregulators (Epitalon, Thymalin, Cortexin): Caution. Combined Vilon and Epitalon changed more cardiac genes than either alone, so effects are not simply additive. Mitigation: do not stack within one course, so any adverse change stays attributable.
Immune-stimulating supplements (echinacea, beta-glucans, medicinal mushroom extracts): Monitor. Additive immune activation, with an unpredictable net immune shift in autoimmune-prone individuals as the consequence. Mitigation: hold immune-stimulating supplements for the duration of the course.
Blood-thinning supplements (fish oil, nattokinase, ginkgo, high-dose vitamin E): Monitor. Additive bleeding tendency on top of Vilon’s reported increase in clot breakdown. Mitigation: reduce or separate high-dose fish oil and nattokinase during a Vilon course.
Other interventions (therapeutic radiotherapy): Caution. Vilon blocked radiation-induced lymphocyte death in rats, which could shield damaged cells from clearance. Mitigation: do not run a Vilon course during or immediately after radiotherapy.

Populations who should avoid Vilon:

Anyone with active or recent malignancy, and in particular anyone within five years of a HER2-positive breast cancer diagnosis
Anyone receiving cytotoxic chemotherapy, or within 30 days of the last cycle
Solid-organ transplant recipients on immune-suppressing drugs such as ciclosporin or tacrolimus, and anyone on prednisone at 20 mg daily or more for two weeks or longer
Anyone with autoimmune disease in active flare, such as systemic lupus erythematosus (an autoimmune disease attacking multiple organs) with active kidney involvement, or rheumatoid arthritis with a disease activity score above 5.1
Anyone on therapeutic anticoagulation with an international normalised ratio above 3.0, or with a platelet count below 50 × 10⁹/L
Pregnant and breastfeeding women, and anyone under 18 years of age
Carriers of an inherited cancer-predisposition syndrome, such as a harmful BRCA1 or BRCA2 variant (genes whose loss impairs DNA repair) or Li–Fraumeni syndrome (an inherited multi-cancer syndrome)

Risk Mitigation Strategies

Cancer screening current before any course: Mammography and colorectal screening documented within 12 months, plus absence of active malignancy, before starting — this addresses the tumour-promotion signal seen in HER2-driven mice.
Hard separation from cytotoxic chemotherapy: No Vilon within 30 days of a chemotherapy cycle, mitigating the loss of chemotherapy effect and the shortened survival seen when Vilon and cyclophosphamide were given together in mice.
Lowest reported effective dose, in courses rather than continuously: Keep to 10 micrograms daily across 10–20 days, one or two courses yearly, limiting cumulative exposure while long-term safety remains unmeasured.
Microgram-versus-milligram dose verification: Reconstitute and calculate so a single administration delivers micrograms, not milligrams; research vials hold roughly two thousand clinical doses, and this arithmetic error is the likeliest route to gross overdose.
Immune panel before and after each course: Complete blood count with differential plus helper and cytotoxic T-cell and natural killer cell counts, to detect the fall in those populations reported in the one human immune dataset.
Glucose vigilance for anyone on insulin: Increase self-monitoring during and for one week after a course, and reduce insulin pre-emptively in small steps, mitigating hypoglycaemia from the reported insulin-sparing effect.
Batch certificate of analysis for every vial: Require purity above 98% by high-pressure liquid chromatography, a mass confirming 275.3 daltons, and sterility plus endotoxin testing, mitigating contamination, wrong-compound and fever risk.
Explicit stop rule: Discontinue on unexplained fever, enlarged lymph nodes, new bruising or bleeding, and reassess before any further course, limiting exposure to immune overactivation and additive bleeding.

Therapeutic Protocol

Standard course as used by the originating group: 10 micrograms daily by subcutaneous or intramuscular injection for 10 consecutive days, repeated once or twice yearly — the regimen reported from Russian clinical practice by the institute that developed the peptide.
Alternative every-other-day schedule: A variant used in peptide practice gives 10 micrograms every other day across 10 to 20 days, on the reasoning that gene-expression effects outlast the peptide itself. No head-to-head comparison of schedules exists.
Oral alternative: The originating group markets oral capsule forms of its short peptides and has studied oral Vilon in rats. No human comparison of oral with injected dosing exists, and oral bioavailability is unquantified.
Competing approach: single agent versus stacked bioregulators: Russian geriatric practice pairs thymic with pineal peptides in sequential courses, while others use Vilon alone to keep any effect attributable. Neither approach has outcome data favouring it.
Best time of day: No chronobiology data exist. Morning administration is conventional in the Russian protocols, though thymic hormone output itself peaks overnight, so the convention rests on practice rather than timing evidence; evening dosing has never been compared.
Half-life and dose splitting: Free dipeptides clear from plasma within minutes, so the single daily microgram dose is not split. The rationale is a durable effect on gene activity rather than sustained blood levels.
Genetic polymorphisms influencing dose choice: No pharmacogenetic guidance exists. Peptide-transporter (PEPT1) variants would in principle alter oral absorption, and HER2 amplification is a reason to withhold rather than to adjust dose.
Sex-based differences: No sex-specific dosing has been studied. All rodent efficacy work used females and the human studies did not stratify, so identical protocols for men and women reflect absence of data.
Age-related considerations: No age-based adjustment is described, yet the target effect is age-dependent: cell-level responses appeared in tissue from people aged 75 to 88 and were absent in young tissue.
Baseline biomarker levels influencing response: A low naive T-cell fraction, a low helper-to-cytotoxic T-cell ratio and a raised high-sensitivity C-reactive protein (an inflammation marker) are the plausible response predictors. None has been validated for Vilon.
Pre-existing conditions influencing response: All three human reports came from disease populations, stage III colorectal cancer and type 1 diabetes, so response in metabolically healthy adults is extrapolation rather than observation.

Discontinuation & Cycling

Course-based by design, not lifelong: Vilon is given in short courses rather than continuously. The originating protocols specify 10 to 20 days once or twice yearly, so stopping is built into ordinary use rather than being a separate decision.
No withdrawal effects reported: No withdrawal syndrome, rebound immune suppression or dependence has been described in any published study, although no study has systematically looked for one after discontinuation.
No tapering protocol: Because courses are short and the peptide clears within minutes, no taper exists or has been proposed. Treatment simply ends at the last scheduled dose.
Cycling rationale and interval: Cycling is the intended pattern, justified by the claim that changes in gene activity persist after the peptide is gone. Reported intervals are six to twelve months; no interval has been tested against another.
Reasons to stop permanently: A new cancer diagnosis, the start of cytotoxic chemotherapy, unexplained enlarged lymph nodes, or a fall in helper T-cell or natural killer cell counts are reasons to end use rather than pause it.

Sourcing and Quality

Regulatory reality of supply: Vilon is a registered medicine in Russia and nothing anywhere else. Outside Russia it is sold as research-use-only powder, so no pharmaceutical-grade consumer product exists in the United States, United Kingdom or European Union.
Identity and purity documentation: A batch-specific certificate of analysis should show purity above 98% by high-pressure liquid chromatography and a mass-spectrometry peak at 275.3 daltons, confirming the two-residue lysine–glutamic acid sequence rather than a longer or scrambled peptide.
Sterility and endotoxin testing: Anything injected needs documented sterility and endotoxin limits. Most research-chemical certificates cover purity only, and that absence is the concrete quality gap for an injected product.
Formulation and handling: Supplied as lyophilised (freeze-dried) powder. Reconstitute with bacteriostatic water, refrigerate and treat the solution as short-dated; dry-powder potency depends on cold-chain storage that research suppliers rarely document.
Brands and compounding routes: No third-party-verified consumer brand exists. United States compounding pharmacies cannot lawfully prepare it, because lysyl-glutamic acid is not an eligible bulk drug substance, leaving Russian pharmacy product as the only pharmaceutical-grade source.

Practical Considerations

Time to effect: The reported courses run 10 to 20 days, and the human reports assessed outcomes over months to two years. No study reports a time-to-effect for any subjective change, so nothing can be expected on a known timescale.
Common pitfalls: The dominant error is dosing in milligrams because vials are sold in 20 milligram quantities while the clinical dose is 10 micrograms, a two-thousand-fold gap. Stacking several bioregulators at once is the second, since nothing is then attributable.
Regulatory status: Not approved by the United States Food and Drug Administration for any use, not lawful as a dietary supplement, and not on the eligible list for pharmacy compounding. It is a registered immune medicine only in Russia.
Cost and accessibility: Cost is not the barrier; research-grade vials are inexpensive relative to the clinical dose. Access is, and it runs entirely through unregulated channels with no pharmacist or prescriber involved.
Payer incentives and structural bias: Vilon is cheap; branded thymic peptides such as thymosin alpha-1 cost far more. Neither is reimbursed for longevity use, so no insurer or health system has a systematic incentive favouring either, and guideline silence reflects absent evidence, not payer pressure.

Interaction with Foundational Habits

Sleep: Direction: none documented. No study has measured sleep on Vilon, and no sedating or stimulating effect has been reported. The one mechanistic link is indirect — thymic hormone output peaks overnight — so the Russian convention of morning dosing rests on no sleep interaction at all.
Nutrition: Direction: potentially blunting for oral forms. Oral dipeptides compete with dietary di- and tripeptides for the intestinal peptide transporter, so an oral dose taken with a protein-heavy meal is likely absorbed less; separating it from meals is the practical step. Injected dosing is unaffected.
Exercise: Direction: indirect and complementary, not blunting. Nothing suggests interference with training adaptation, and no human study measured performance, though treated mice increased spontaneous activity and endurance. Exercise independently supports immune surveillance, so the two plausibly point the same way without demonstrated interaction.
Stress management: Direction: opposing. Sustained cortisol elevation is a principal driver of thymus shrinkage, so unmanaged chronic stress works against the effect Vilon is intended to produce. No study has measured cortisol on Vilon, though treated rats resisted emotional stress and kept their thymus; the interaction in people is inferred from thymic biology.

Monitoring Protocol & Defining Success

Baseline testing before a first course does two things: it fixes the immune and clotting values Vilon has been reported to move, and it excludes the conditions that make the peptide inadvisable. A complete blood count with differential, lymphocyte subsets, a metabolic panel with kidney function, fasting glucose with glycated haemoglobin (average blood sugar over about three months), a clotting panel and high-sensitivity C-reactive protein cover both, alongside documentation that age-appropriate cancer screening is current.

Because a course lasts only 10 to 20 days, ongoing monitoring is tied to the course rather than to the calendar: repeat the immune and clotting panels at the end of each course and again at 4 to 6 weeks, then at 6 to 12 month intervals if courses continue. Anyone on insulin or an anticoagulant needs checks within the first week of every course.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
Complete blood count with differential	Lymphocytes 1.5–3.0 × 10⁹/L; neutrophil-to-lymphocyte ratio below 2.0	Detects lymphoid overgrowth or suppression	Fasting not required. Conventional laboratories accept lymphocytes up to 4.0 × 10⁹/L, a looser ceiling than the functional target. Pair with the subsets below.
Helper (CD4) and cytotoxic (CD8) T-cell counts and ratio	CD4:CD8 ratio 1.5–2.5	Helper T cells fell in the one human dataset on Vilon	CD4 and CD8 are surface markers naming the two main T-cell types. Draw in the morning at the same laboratory each time; the ratio is more stable than absolute counts.
Natural killer cell count	150–500 cells/µL, or 7–20% of lymphocytes	The second cell population reported to fall during treatment	Natural killer cells destroy infected and tumour cells. Counts are sensitive to acute stress and recent hard exercise; avoid sampling within 24 hours of heavy training.
Naive CD4 T-cell fraction	Above 30% of CD4 cells at age 60 and over	Closest available readout of thymic output, the intended target	No established target exists below that age; track change from the individual’s own baseline. Requires specialist flow cytometry and is not on standard panels.
Antithrombin III activity	80–120%	Vilon raised this natural anticoagulant; rising values with bleeding signs warrant stopping	Draw before any anticoagulant is started. Heparin lowers measured activity, so interpret only against a pre-treatment baseline.
Protein C activity	70–140%	The second anticoagulant protein reported to rise	Vitamin K antagonists such as warfarin lower it. Interpret only against a baseline taken before anticoagulation.
International normalised ratio and activated partial thromboplastin time	International normalised ratio 0.9–1.1 if not anticoagulated; within the prescribed therapeutic window if anticoagulated	Catches additive anticoagulant effect	The international normalised ratio is a standardised clotting time; activated partial thromboplastin time covers a second clotting route. Check within one week of starting a course in anyone anticoagulated.
Fasting glucose and glycated haemoglobin	Glucose 70–85 mg/dL; glycated haemoglobin below 5.4%	Vilon reduced insulin requirement, making low blood sugar the exposure	Glycated haemoglobin reflects average glucose over about three months. Conventional cut-offs are looser, at below 5.7%. Requires a 12-hour fast.
High-sensitivity C-reactive protein	Below 0.5 mg/L	General inflammation, which rises with immune overactivation	An inflammation marker. Invalid within two weeks of infection or injury. Conventional laboratories flag only values above 3.0 mg/L, six times looser than the functional ceiling. Pair with interleukin-6 (a signalling protein that drives it) where available.
Estimated glomerular filtration rate with creatinine	Above 90 mL/min/1.73 m²	Kidney signalling was the one non-immune animal finding, and function gates drug interactions	The estimated glomerular filtration rate estimates kidney filtration. The conventional cut-off for normal is 60, far lower than the functional target. Avoid heavy protein or creatine the day before.
Age-appropriate cancer screening status	No established range; mammography, colorectal and skin screening documented as current	The tumour-promotion signal makes this the decisive safety gate	Not a biomarker in range terms. Record the date and result of each screen rather than a value, and track that record forward.
Epigenetic age estimate	No established target; track change from the individual’s own baseline	The proposed mechanism acts on gene activity, and this is the only integrative readout available	Commercial estimators differ widely between providers. Use one provider and one sample type throughout, and sample at a consistent time of day.

Qualitative markers worth tracking alongside the laboratory values:

Infection frequency and duration: number of upper-respiratory episodes and days to resolution across a year, compared with the preceding year
Recovery from exertion: days needed to feel recovered after a hard training session
Energy and daytime alertness: a simple one-to-ten daily rating, averaged weekly
Sleep quality: time to fall asleep and number of night wakings, since no interaction is documented and any change would itself be new information
Cognitive clarity: subjective ease of sustained focus, rated weekly
Local tolerance: presence, size and duration of injection-site redness or swelling
Warning signs: unexplained fever, enlarged or tender lymph nodes, easy bruising, nosebleeds

Emerging Research

No registered trial of Vilon: A search of ClinicalTrials.gov returns no interventional study of Vilon, and none of its Russian trials appears in any international registry. Every claim about human effects therefore rests on three small unregistered reports, two of them overlapping, which is the largest single gap in the evidence base.
Thymus regeneration as a testable premise: NCT04375657, a Phase 2 trial of 85 volunteers aged 40 to 80 run by Intervene Immune, combines growth hormone, metformin and the adrenal hormone dehydroepiandrosterone, with thymic density on imaging and epigenetic age as primary endpoints. A positive result strengthens the premise Vilon targets; a null result weakens it.
Thymic peptide immunomodulation in older adults: NCT06821100 is a randomised Phase 1 trial in 75 adults aged 65 and over, testing whether thymosin alpha-1, an approved thymic peptide, improves antibody and T-cell responses to vaccination. It is the nearest registered test of the therapeutic category Vilon belongs to.
Epigenetic age reversal as the benchmark result: Fahy et al., 2019 reported thymic regeneration alongside a roughly two-year fall in one epigenetic age estimate in a small uncontrolled study. That is the result the larger trial above is designed to confirm, and the standard any Vilon claim would have to meet.
Independent replication of peptide–DNA binding: The promoter-recognition model was set out in Khavinson et al., 2021, a systematic review from the originating group. Binding assays and transcriptional readouts on the named motifs, run by a laboratory with no commercial interest, would settle whether the mechanism is real.
Packed-genetic-material findings from a second group: Lezhava et al., 2023 extended the work on loosening packed genetic material to four short peptides in cells from people aged 75 to 88, reporting region-selective effects. Whether loosening helps or destabilises the ageing genome is the open question that could cut either way.
Oncology direction that could weaken the case: The transgenic mouse result of Anisimov et al., 2002 has never been followed up in a HER2-driven model with modern endpoints. A repeat showing the same tumour acceleration would effectively close the question for anyone carrying breast-cancer risk.

Conclusion

Vilon is a two-amino-acid molecule made in Russia in the 1990s as a defined replacement for thymus extracts, on the premise that a molecule this small can enter the nucleus of a cell and switch particular genes back on. Its stated purpose is to restore immune function that fades as the thymus shrinks with age, and from there to slow age-related decline.

What the literature supports is thin and uneven. The laboratory work is internally consistent: in cells from very old people the peptide loosens tightly packed genetic material and shifts the activity of genes tied to stress resistance and repair, and in old mice it lengthened life and reduced spontaneous tumours. Human evidence amounts to three small unregistered reports — one in older people with advanced bowel cancer, suggesting fewer complications and longer survival, and two in older people with diabetes, reporting lower insulin needs and shifts in clotting proteins. Neither strand has been repeated.

Against that sits a real warning. In mice bred to develop breast tumours, Vilon made the cancer worse rather than better, and given at the same time as a standard chemotherapy drug it cancelled that drug’s effect and shortened survival. The diabetes report also described falls in two immune cell populations the peptide is meant to support.

Almost all of this comes from one institute that developed the peptide, patented it and sells it, and no independent group has confirmed either the mechanism or the clinical claims. The evidence stays preliminary in both directions.

Top - Benefits - Risks - Protocol

Vilon for Health & Longevity

Motivation

Recommended Reading

Grokipedia

Examine

ConsumerLab

Systematic Reviews

Mechanism of Action

Historical Context & Evolution

Expected Benefits

High 🟩 🟩 🟩

Medium 🟩 🟩

Fewer Complications and Longer Survival When Added to Colorectal Cancer Treatment in Older Adults

Low 🟩

Lower Insulin Requirement and Shifted Coagulation Markers in Older Adults With Type 1 Diabetes

Speculative 🟨

Immune Restoration Through Thymic Stimulation

Longer Lifespan and Better Physical Endurance in Mice

Reduced Tumour Incidence in Rodent Carcinogenesis Models ⚠️ Conflicted

Epigenetic Reactivation of Aged Human Cells

Lower Scarring Signals and Vessel Leak in Rodent Kidney Failure

Protection of Lymphocytes From Radiation-Induced Cell Death

Improved Small-Intestine Enzyme Activity in Old Rats

Activated Sexual Function and Lower Prolactin in Old Male Rats

Greater Resistance to Emotional Stress in Rats

Suppressed Inflammatory Signalling in Human Monocyte Cultures

Weak Liver Regeneration in Cirrhotic Rats

Benefit-Modifying Factors

Potential Risks & Side Effects

High 🟥 🟥 🟥

Medium 🟥 🟥

Low 🟥

Reduction in Helper T Cells and Natural Killer Cells

Hypoglycaemia When Combined With Insulin or Other Glucose-Lowering Treatment

Speculative 🟨

Tumour Promotion in Predisposed Tissue ⚠️ Conflicted

Antagonism of Cytotoxic Chemotherapy

Unwanted Lymphoid Proliferation and Suppressed Cell Turnover

De-Repression of Normally Silenced Genome Regions

Contamination, Mislabelling and Injection-Site Reactions From Research-Grade Supply

Risk-Modifying Factors

Key Interactions & Contraindications

Risk Mitigation Strategies

Therapeutic Protocol

Discontinuation & Cycling

Sourcing and Quality

Practical Considerations

Interaction with Foundational Habits

Monitoring Protocol & Defining Success

Emerging Research

Conclusion